Research To Practice | Oncology Videos

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Tail on the Curve? (0:00)
• First-Line Chemoimmunotherapy (10:45)
• Maintenance Lurbinectedin (28:42)
• Second-Line Treatment, Tarlatamab (45:35)
• Ongoing Research (53:20)

Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics: 

• Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00)
• Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24)
• Case: A...

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics: 

• Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00)
• Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15)
• Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline ...

Featuring perspectives from Dr Kerry Rogers, moderated by Dr Stephen "Fred" Divers, including the following topics: 

• Chronic Lymphocytic Leukemia (CLL) — Dr Rogers (0:00)
• Case: A man in his mid 70s with CLL and a history of atrial fibrillation — Dr Lamar (13:08)
• Case: A fit man in his early 80s with IGHV-unmutated, TP53-mutant symptomatic CLL — Dr Mulherin (21:16)
• Case: ...

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics: 

• Introduction (0:00)
• Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32)
• Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta ...

Featuring perspectives from Dr Jeremy S Abramson and Dr Loretta J Nastoupil, including the following topics:

• Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (0:00)
• Potential Treatment Benefits of CAR T-Cell Therapy (13:31)
• Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome (28:13)
• Finding Information About CAR T-Cell Therapy; Clinical Trials (36:28)
• Financial Is...

Featuring an interview with Dr John V Heymach, including the following topics:

• Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00)
• Activity of targeted agents across HER2 alterations in NSCLC (4:06)
• Available data with zongertinib and sevabertinib for HER2-mutant NSCLC (20:39)
• Case: A man in his late 40s with HER2-mutant NSCLC receives multiple lines of thera...

Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics:

• Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00)
• Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03)
• Clinical data with zongertinib for HER2-mutant NSCLC (6:35)
• Emerging data with sevabertinib for HER2-mutant NSCLC (14:41)
• ...

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00)
  • Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstra...

Featuring an interview with Dr Matthew Lunning, including the following topics:

• Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00)
• Overview of the CAR T-cell therapy administration process (4:40)
• Opportunities for referral for CAR T-cell therapy (10:05)
• Selection of a CAR T-cell therapy based on patient characteristics (16:09)
• Sequencing of CAR T-cell therapy for vario...

Featuring a slide presentation and related discussion from Dr Matthew Lunning, including the following topics:

• Overview of available chimeric antigen receptor (CAR) T-cell therapies (0:00)
• Toxicities associated with CAR T-cell therapy (4:03)
• Mitigation strategies for adverse events (22:02)
• Novel strategies for outpatient infusion (26:34)
• Changes to the CAR T-cell therapy safety regulations (30:23)

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• Patient-reported outcomes from the SERENA-6 trial of camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer and ESR1 mutations emerging during first-line endocrine-based therapy (0:00)
  • Mayer E et al. Patient-reported outcomes (PROs) from t...

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: 

• Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)
• SERD Monotherapy (13:34)
• SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)
• SERDs for "Molecular Progression" — The SERENA-6 Study (41:25)

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00)
  • Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emt...

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor, including the following topics:

• Introduction: Assessment of HER2 Status (0:00)
• Case: An otherwise healthy woman in her early 50s with HER2-positive metastatic gallbladder cancer and multiple intrahepatic metastases — Jeremy Lorber, MD (7:33)
• Case: A man in his late 6...

Featuring an interview with Dr Erika Hamilton, including the following topics:

• General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)
• Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant br...